BioCardia has announced the publication of data from the initial open-label roll-in cohort that served as the precursor for the ongoing CardiAMP Heart Failure (HF) phase III clinical trial. Published in the International Journal of Cardiology, the study data shows that CardiAMP is a well-tolerated treatment in heart failure patients and demonstrated improved distance in six-minute exercise testing at six months and a trend toward improvement at one year. This 10-patient cohort was the feasibility test for the currently enrolling CardiAMP HF Phase 3 clinical trial.
A study published in the Journal of the American College of Cardiology (JACC) has identified different types of cardiac structural damage experienced by COVID-19 patients after cardiac injury that can be associated with deadly conditions including heart attack, pulmonary embolism, heart failure, and myocarditis.
Tricupsid annular dilatation (TAD) is an independent predictor of all-cause mortality in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI), a study published in JACC: Cardiovascular Interventions has found.
Rhian E Davies (University of Washington Medical Center, Seattle, USA) discusses a recent paper considering the importance of training in high-risk percutaneous coronary intervention (PCI) procedures, as well as a renewed interest in both the development of this skillset outside of fellowship and maintenance of competency.
Results of the OPTIMIZE IDE study, assessing the Svelte drug-eluting stent (DES) Integrated Delivery System (SLENDER IDS) and Rapid Exchange (DIRECT RX) platforms (Svelte Medical Systems) were presented at TCT Connect 2020 (14 – 18 October, virtual). The study showed that use of the devices resulted in a 1.5% clinically-driven target lesion revascularisation (TLR) at one-year.
Biosensors has announced the award of a CE mark for BioFreedom Ultra drug-coated coronary stent system. BioFreedom Ultra is a novel thin strut (84µm) CoCr polymer and carrier-free drug-coated stent with Biosensors’ proprietary Biolimus A9 drug. BA9 is Biosensors’ proprietary highly lipophilic anti-restenotic drug, developed specifically for use in coronary vascular applications.
CeloNova BioSciences has announced interim results from the randomised Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE), the first randomised 14-day dual antiplatelet therapy (DAPT) study of high bleeding risk patients (HBR), during a late-breaking clinical science session at TCT Connect 2020 (14–18 October, virtual).
One-year clinical outcomes from the global EXPAND study, reporting on the use of the third generation MitraClip (Abbott) NTR and XTR systems, show that the device achieves improvements in mitral regurgitation compared to previous Mitraclip generations, which are maintained at one-year. The results were presented during a late breaking clinical science session at TCT Connect 202 (14–18 October) by Saibal Kar (Cedars-Sinai Medical Center, Los Angeles, USA).
An interim analysis of the Restore EF Study, presented at TCT Connect 2020 (14–18 October, virtual), demonstrates the use of contemporary best practices, including attempting a more complete revascularisation with Impella-supported high-risk percutaneous coronary intervention (PCI), is associated with significant improvement of left ventricular ejection fraction (LVEF), heart failure symptoms, and anginal symptoms at follow-up. The analysis was presented by Mitul Patel, MD, an interventional cardiologist at UC San Diego Health, San Diego, USA.
Medtronic has today announced plans to launch a randomised, head-to-head study comparing two transcatheter aortic valve implant (TAVI) devices in patients with severe symptomatic aortic stenosis (ssAS). The SMall Annuli Randomized To Evolut or Sapien (SMART) post-market trial will compare valve safety and performance of the self-expanding Medtronic Evolut PRO and PRO+TAVR Systems against the balloon-expandable SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valves manufactured by Edwards Lifesciences.
A recent randomised controlled trial (RCT)—the CIPIC Rehab study—found that three-months’ community-based cardiac rehabilitation improves walking distance in patients with intermittent claudication. It was also found to improve physical activity level, diet, and health-related quality of life. These results were presented by Maj Siercke (University of Copenhagen, Copenhagen, Denmark) during ESVS Month (29 September–29 October), the digital replacement for this year’s European Society for Vascular Surgery (ESVS) annual meeting.
Javier Escaned (Hospital Universitario Clínico San Carlos, Madrid, Spain) discusses the increased interest in coronary microcirculation and non-obstructive coronary artery disease
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389